Hussain M, et al. PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. ESMO Congress 2019, abstract LBA12_PR.
Prevalentie en mortaliteit van COVID-19 bij patiënten met kanker
okt 2020 | Leukemie, Lymfoom, MM